Tags (14) : biotechnology
Volta Labs Launches Automated DNA Prep for Oxford Nanopore Sequencing
05/25/2026 | Companies
AGBT 2026,
automated sample preparation,
biotechnology,
Callisto Sample Prep System,
clinical diagnostics,
DNA library preparation,
genomic sequencing,
genomics,
high molecular weight DNA extraction,
ISO 15189,
laboratory automation,
ligation sequencing kit,
Oxford Nanopore Technologies,
PromethION platform,
sequencing technology,
SNV recall,
SQK-LSK114,
UMC Utrecht,
Volta Labs,
whole genome sequencing
Vector Science & Therapeutics Partners With MPP Group LLC to Advance Peptide Therapeutics
05/11/2026 | Companies
analytical testing,
aseptic manufacturing,
biotechnology,
cGMP manufacturing,
clinical peptide applications,
contract manufacturing organization,
drug development,
FDA-registered facility,
MPP Group LLC,
peptide compounding,
peptide delivery systems,
peptide formulations,
peptide market,
peptide stability,
peptide therapeutics,
pharmaceutical manufacturing,
pharmaceutical-grade peptides,
physician-supervised therapeutics,
regulated drug manufacturing,
shelf-stable peptides,
therapeutic peptides,
transdermal drug delivery,
transdermal technology,
Vector Science & Therapeutics,
Wisconsin biotech
FDA Modernization Act 2.0 and the Future of Non-Animal Models
05/04/2026 | Companies
2D cell cultures,
3D human biology,
96-well functional platforms,
automated hardware,
automated recording,
biotechnology,
cardiac research,
contractile force analysis,
drug development,
Duchenne muscular dystrophy,
electrophysiology,
FDA Modernization Act 2.0,
fluorescence readouts,
high-throughput screening,
human-relevant data,
life sciences webinar,
NAMs,
neuromuscular research,
neurotoxin potency testing,
Non-Animal Models,
optogenetics,
organ-on-a-chip,
pharmaceutical industry,
predictive modeling,
quantitative analysis,
regulatory science,
safety pharmacology,
skeletal muscle research,
toxicology research
Lakewood-Amedex Appoints Joseph Tucker to Board After Nasdaq Listing
04/28/2026 | Companies
antibiotic resistance,
antimicrobial drugs,
biotech leadership,
biotechnology,
Bisphosphocin,
board of directors,
capital markets,
clinical trials,
clinical-stage biotech,
corporate governance,
diabetic foot ulcers,
drug development,
Enveric Biosciences,
healthcare innovation,
Joseph Tucker,
Lakewood-Amedex Biotherapeutics,
Nasdaq listing,
neurological disorders,
neuropsychiatric disorders,
Nu-3,
pipeline development,
small-molecule therapeutics,
strategic growth
Arcera–Fosun Pharma MoU to Boost Global Life Sciences & Neuroscience Innovation
04/28/2026 | Companies
Abu Dhabi,
Alzheimer’s disease,
Arcera Life Sciences,
biologics,
biotechnology,
biotechnology incubation,
cardiometabolic diseases,
cell therapy,
China,
drug development,
emerging markets,
Fosun Pharma,
gene therapy,
global healthcare,
healthcare infrastructure,
innovation,
international collaboration,
joint ventures,
licensing,
life sciences,
market access,
memorandum of understanding,
Middle East healthcare,
MoU,
neurodegenerative diseases,
neuroscience,
oncology,
pharmaceutical industry,
R&D,
radiopharmaceuticals,
rare diseases,
research and development,
siRNA therapies,
small molecules,
strategic partnership,
UAE,
Vision 2030
Intensity Therapeutics Wins 2026 Pinnacle Award for INT230-6 Cancer Therapy
04/16/2026 | Companies
biotech awards,
biotech solutions,
biotechnology,
cancer therapy,
cancer treatment development,
cisplatin,
clinical research,
drug conjugation technology,
healthcare innovation,
immunotherapy enhancement,
INT230-6,
Intensity Therapeutics,
intratumoral injection,
oncology innovation,
pharmaceutical innovation,
Pinnacle Awards 2026,
SHAO molecule,
solid tumors,
tumor targeting,
vinblastine sulfate
Mabwell Advances 6MW5311 Bispecific Antibody for AML and Blood Cancers
04/16/2026 | Companies
6MW5311,
acute myeloid leukemia,
AML,
biopharmaceuticals,
biotechnology,
bispecific antibody,
cancer research,
CD3,
chronic myelomonocytic leukemia,
clinical trials,
CMML,
cytotoxicity,
drug development,
FDA,
hematologic malignancies,
immune synapse,
immunotherapy,
IND application,
LILRB4,
Mabwell,
MM,
multiple myeloma,
NMPA,
oncology,
preclinical studies,
stem cell transplantation,
steric hindrance,
T cell engager,
targeted therapy,
TCE technology,
tumor inhibition
Insilico Medicine & ASKA Partner to Advance AI-Driven Treatments for Gynecological Diseases
03/25/2026 | Companies
adenomyosis,
AI drug discovery,
artificial intelligence in healthcare,
ASKA Pharmaceutical,
biotechnology,
clinical-stage research,
disease target identification,
drug development,
endometriosis,
generative AI,
gynecological diseases,
Insilico Medicine,
medical innovation,
PandaOmics,
pharmaceutical collaboration,
reproductive health,
TargetPro,
therapeutic targets,
uterine fibroids,
women’s health
Vimgreen Secures IND Approval for VG081821 in NASH Treatment
03/18/2026 | Companies
A2A receptor antagonist,
adenosine signalling,
biotechnology,
China CDE,
clinical trials,
drug development,
fibrosis,
hepatology,
IND approval,
inflammation,
inverse agonist,
lipophagy,
liver disease,
MASH,
metabolic disorders,
metabolic dysfunction associated steatohepatitis,
NASH,
non alcoholic steatohepatitis,
Parkinsons disease,
Phase II trial,
resmetirom,
semaglutide,
steatosis,
VG081821,
Vimgreen Pharmaceuticals
HotSpot Therapeutics, Inc. to Present IRF5 Lupus Preclinical Data at European Lupus Meeting 2026
02/26/2026 | Companies
Hyundai Bioscience Launches U.S. Phase 2 Trials for Broad-Spectrum Antiviral Xafty
01/15/2026 | Companies
antiviral drug development,
basket trial,
Biotech Showcase 2026,
biotechnology,
broad-spectrum antiviral,
clinical research,
COVID-19 variants,
dengue fever,
FDA IND application,
global health,
Hyundai Bioscience,
infectious diseases,
influenza,
multi-viral treatment,
pharmaceutical innovation,
Phase 2 clinical trials,
public health strategy,
RSV,
tripledemic,
viral epidemics,
virus prevention,
Xafty
Breakthrough HIV Treatment: Gilead's Innovative Drug Discovery Journey
04/03/2025 | Companies
antiviral therapy,
biopharmaceuticals,
biotechnology,
breakthrough medicine,
clinical trials,
drug discovery,
drug resistance,
Gilead,
global health,
healthcare innovation,
HIV,
HIV prevention,
HIV research,
HIV treatment,
medical innovation,
medical science,
pharmaceutical development,
Tomas Cihlar,
viral capsid,
virology
Brii Biosciences Acquires Full Rights to BRII-179 for HBV Cure Advancement
01/01/2025 | Companies
biotechnology,
Brii Biosciences,
BRII-179,
clinical trials,
combination therapies,
drug development,
elebsiran,
ENRICH study,
functional cure,
HBV,
healthcare innovation,
Hepatitis B Virus,
intellectual property acquisition,
know-how,
patents,
PEG-IFNα,
Phase 2b study,
shareholder value,
unmet medical needs,
VBI Vaccines
Most Popular Now
Environment News
Compliance
Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com


Companies